Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for CymaBay Therapeutics

    Client Virtual Booth

    CYMABAY THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    CymaBay Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    7575 Gateway Blvd., Suite 110 Newark, CA 94560
    Telephone
    Telephone
    +1 (510) 293-8800
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cymabay.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Gilead Announces Expiration of Waiting Period for CymaBay Tender Offer
    Gilead Announces Expiration of Waiting Period for CymaBay Tender Offer

    https://www.businesswire.com/news/home/20240311327601/en

    BUSINESSWIRE
    11 Mar 2024
    Share Share
    CymaBay Announces EMA Accepts for Review the MAA for Seladelpar
    CymaBay Announces EMA Accepts for Review the MAA for Seladelpar

    https://www.globenewswire.com//news-release/2024/03/04/2839523/37067/en/CymaBay-Announces-European-Medicines-Agency-Accepts-for-Review-the-Marketing-Authorization-Application-for-Seladelpar-for-the-Treatment-of-Primary-Biliary-Cholangitis.html

    GLOBENEWSWIRE
    04 Mar 2024
    Share Share
    CymaBay Reports Fourth Quarter & Year Ended December 31, 2023 Financial Results
    CymaBay Reports Fourth Quarter & Year Ended December 31, 2023 Financial Results

    https://www.globenewswire.com//news-release/2024/02/28/2837495/37067/en/CymaBay-Reports-Fourth-Quarter-and-Year-Ended-December-31-2023-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    28 Feb 2024
    Share Share
    CymaBay board pushed for 50 cent top up to Gilead's $32.50 offer
    CymaBay board pushed for 50 cent top up to Gilead's $32.50 offer

    https://www.fiercebiotech.com/biotech/cymabay-board-pushed-50-cent-top-gileads-3250-share-offer

    Annalee Armstrong FIERCE BIOTECH
    26 Feb 2024
    Share Share
    The New England Journal Publishes Positive Phase 3 of CymaBay's Seladelpar
    The New England Journal Publishes Positive Phase 3 of CymaBay's Seladelpar

    https://www.prnewswire.com/news-releases/the-new-england-journal-of-medicine-publishes-positive-phase-3-response-data-of-cymabays-seladelpar-in-primary-biliary-cholangitis-302068089.html

    PR NEWSWIRE
    21 Feb 2024
    Share Share
    CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    https://www.globenewswire.com//news-release/2024/02/20/2832269/37067/en/CymaBay-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    20 Feb 2024
    Share Share
    Cymabay Therapeutics Investor Alert By The Former Attorney General Of Louisiana
    Cymabay Therapeutics Investor Alert By The Former Attorney General Of Louisiana

    https://www.businesswire.com/news/home/20240216171507/en

    BUSINESSWIRE
    16 Feb 2024
    Share Share
    Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
    Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

    https://www.gilead.com/news-and-press/press-room/press-releases/2024/2/gilead-sciences-expands-liver-portfolio-with-acquisition-of-cymabay-therapeutics

    PRESS RELEASE
    13 Feb 2024
    Share Share
    CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar
    CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar

    https://www.prnewswire.com/news-releases/cymabay-announces-fda-acceptance-of-nda-and-priority-review-for-seladelpar-for-the-treatment-of-primary-biliary-cholangitis-302059522.html

    PR NEWSWIRE
    12 Feb 2024
    Share Share
    CymaBay Therapeutics to Participate in Upcoming Investment Conferences
    CymaBay Therapeutics to Participate in Upcoming Investment Conferences

    https://www.globenewswire.com/news-release/2024/01/31/2821052/37067/en/CymaBay-Therapeutics-to-Participate-in-Upcoming-Investment-Conferences.html

    GLOBENEWSWIRE
    31 Jan 2024
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search